Bayer’s sweeping executive cuts, Wegovy’s expanding reach
27 Mar 2024
16m
BioSpace · Business
BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
Money talk: Salary trends and raises
21 Mar 2024
15m
Historic approval for MASH, CAR-Ts in the spotlight
20 Mar 2024
17m
The unintended consequences of small molecules
14 Mar 2024
24m
The skinny on weight loss, donanemab and the State of the Union
13 Mar 2024
15m
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
06 Mar 2024
11m
The gap is where the pain is: Drug pricing and patient costs
29 Feb 2024
20m
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
28 Feb 2024
14m
Iovance wins with Amtagvi and the ADC train chugs on
21 Feb 2024
13m
Eyes on the prize: Novo buys Catalent
14 Feb 2024
29m
Balancing act: Patient access and innovation
07 Feb 2024
20m
Keep calm and CAR-T on?
31 Jan 2024
17m
What can biopharma expect from the job market?
25 Jan 2024
18m
Grab an umbrella, it's raining IPOs!
24 Jan 2024
10m
Optimistic, but for how long? Our big takeaways from #JPM2024
17 Jan 2024
13m
On the ground at #JPM2024 - Day 3 highlights
10 Jan 2024
12m
On the ground at #JPM2024 - Day 2 highlights
10 Jan 2024
12m
On the ground at #JPM2024 - Day 1 highlights
08 Jan 2024
10m
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
04 Jan 2024
48m
The top life sciences startups to watch this year
03 Jan 2024
14m
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.